Coherus Oncology (CHRS) Enterprise Value (2013 - 2026)
Coherus Oncology (CHRS) reported Enterprise Value of -$167.0 million for Q1 2026, down 102.7% on a YoY basis from $6.2 billion in Q1 2025, and up 2.95% sequentially from -$172.1 million in Q4 2025.
Coherus Oncology (CHRS) Enterprise Value (2013 - 2026) Analysis & Trends
Coherus Oncology (CHRS) has 14 years of Enterprise Value data on file, last reported at -$167.0 million in Q1 2026.
- For the quarter ending Q1 2026, Enterprise Value fell 102.7% year-over-year to -$167.0 million; the trailing twelve-month figure through Mar 2026 stood at -$167.0 million (down 102.7% YoY), and the FY2025 full-year result was -$172.1 million, down 36.62% from the prior year.
- Enterprise Value improved to -$167.0 million in Q1 2026, from -$172.1 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$82.4 million in Q1 2025 to a low of -$325.7 million in Q1 2022.
- A 5-year average of -$182.1 million and a median of -$167.0 million in 2026 frame the typical range for Enterprise Value.
- Across the five-year window, Enterprise Value tumbled 102.81% in 2024 and surged 68.28% in 2025, its largest moves.
- Tracing CHRS's Enterprise Value over 5 years: stood at -$191.7 million in 2022, then soared by 38.57% to -$117.7 million in 2023, then dropped by 7.0% to -$126.0 million in 2024, then slumped by 36.62% to -$172.1 million in 2025, then rose by 2.95% to -$167.0 million in 2026.
- Business Quant data shows CHRS's Enterprise Value at -$167.0 million in Q1 2026, -$172.1 million in Q4 2025, and -$191.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -283.54 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | -61.40 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | -4.79 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -32.26 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -7.25 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -8.75 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | -5.18 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -1.91 Bn |
| 10 | Coherus Oncology | 195.05 Mn | 28.00 Mn | 8.50 Mn | -167.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -167.05 Mn |
| Dec 31, 2025 | -172.13 Mn |
| Sep 30, 2025 | -191.66 Mn |
| Jun 30, 2025 | -237.64 Mn |
| Mar 31, 2025 | -82.41 Mn |
| Dec 31, 2024 | -125.99 Mn |
| Sep 30, 2024 | -97.69 Mn |
| Jun 30, 2024 | -159.24 Mn |
| Mar 31, 2024 | -259.78 Mn |
| Dec 31, 2023 | -117.75 Mn |
| Sep 30, 2023 | -131.08 Mn |
| Jun 30, 2023 | -144.71 Mn |
| Mar 31, 2023 | -128.09 Mn |
| Dec 31, 2022 | -191.68 Mn |
| Sep 30, 2022 | -286.81 Mn |
| Jun 30, 2022 | -275.48 Mn |
| Mar 31, 2022 | -325.68 Mn |
| Dec 31, 2021 | -417.20 Mn |
| Sep 30, 2021 | -468.71 Mn |
| Jun 30, 2021 | -454.42 Mn |